EFFECTIVENESS AND SAFETY OF INACTIVATED COVID-19 VACCINE IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING ANTI-TNF COMPARED TO HEALTHY EGYPTIAN POPULATION

Document Type : Original Article

Authors

1 Department of Tropical Medicine, Faculty of Medicine, Ain Shams University Hospitals, Cairo 11566, Egypt

2 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University Hospitals, Cairo 11566, Egypt

Abstract

Ulcerative colitis (UC) has been proven to have an economic and physical burden upon patients,
with an associated mortality of up to 2.9%. However, morbidity and mortality have peaked
since the breakout Coronavirus disease 2019 )COVID-19( pandemic as result of direct relationship
between Inflammatory bowel disease (IBD) severity and adverse outcome from severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
This study evaluated the efficacy and safety of inactivated COVID 19 vaccine (e.g. Sinopharm)
in UC patients receiving anti-tumor necrosis factor (TNF) as compared to normal hea lthy
population receiving the same type of vaccine 3 months after the last dose of vaccination.
The results showed those twenty patients with ulcerative colitis and on Anti TNF treatment
(GA), and 20 healthy controls (GB). In GA; the mean age was (31.65) years, included 12
females (60%) and 8 males (40%). While in GB; the mean age was (30.55) years, with 11 males
(55%) and 9 females (45%) without significant difference between both as to age (P=0.459) or
sex (P=0.619). In GA only 16 (80%) had positive anti-spike IgG versus 18 posit- ives in GB
(90%) without significant difference. Anti-spike IgG titre after 3 months with median ranges of
33.5 (RU/ml) in IBD patients and 44.5 (RU/ml) in controls with significant difference between
both (P=0.025). There was no significant difference between both groups as to pain at injection
site, skin allergy and generalized symptoms (fatigue, fever, chills, headache, muscles and joints
pain).

Keywords

Files

Share

How to cite

Statistics